Learn About T-Cell Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
City Of Hope Medical Foundation
Christiane Querfeld is a Dermatologist in Newport Beach, California. Dr. Querfeld and is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.
University Of Virginia Physicians Group
Enrica Marchi is an Oncologist and a Hematologist in Charlottesville, Virginia. Dr. Marchi and is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Marchi is currently accepting new patients.
City Of Hope Medical Foundation
Jasmine Zain is a Hematologist and a Hematologist Oncology provider in Newport Beach, California. Dr. Zain and is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Summary: A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Summary: DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL...